Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merz drops Obagi bet after Valeant raises bid

This article was originally published in Scrip

Executive Summary

Valeant Pharmaceuticals' revised bid to buy dermatology specialist Obagi Medical Products was too rich for Merz Pharma Group's blood, so the German company dropped its public offer to buy Obagi after Valeant raised its acquisition price to $24 per share.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020968

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel